Healthcare

In its quarter ended 30 June 2026 update, EVE Health Group (ASX:EVE) said the Libbo pilot study protocol had been finalised, with a contract research organisation and clinical site engaged. The company indicated that pilot dosing was expected in the fourth quarter of 2026, …

Nova Eye Medical Limited (ASX:EYE) operates in ophthalmic devices for glaucoma treatment. In 2026, its activities are viewed through the practical requirements of iTrack Advance illuminated microcatheter and canaloplasty: product design, evidence, counterparties and the rules governing use in relevant markets. The distinction between …

Firebrick Pharma Limited (ASX:FRE) operates in upper respiratory health products centred on povidone-iodine formulations. In 2026, its activities are viewed through the practical requirements of Nasodine nasal spray and regional registration requirements: product design, evidence, counterparties and the rules governing use in relevant markets. …

Imagion Biosystems Limited (ASX:IBX) operates in medical imaging research involving magnetic nanoparticle technology. In 2026, its activities are viewed through the practical requirements of surface-functionalised magnetic nanoparticles and molecular targeting: product design, evidence, counterparties and the rules governing use in relevant markets. The distinction …

Island Pharmaceuticals Limited (ASX:ILA) operates in clinical-stage therapies addressing infectious diseases. In 2026, its activities are viewed through the practical requirements of ISLA-101 and Galidesivir antiviral programs: product design, evidence, counterparties and the rules governing use in relevant markets. The distinction between the underlying …

Immuron Limited (ASX:IMC) operates in oral antibody-based products and research for gastrointestinal infections. In 2026, its activities are viewed through the practical requirements of bovine colostrum-derived polyclonal antibody technology: product design, evidence, counterparties and the rules governing use in relevant markets. The distinction between …

Immutep Limited (ASX:IMM) operates in clinical-stage cancer immunotherapy based on the LAG-3 immune pathway. In 2026, its activities are viewed through the practical requirements of eftilagimod alfa and immune-system modulation: product design, evidence, counterparties and the rules governing use in relevant markets. The distinction …